Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
XtalPi Holdings Ltd (2228.HK)
Shenzhen, CN
XtalPi Holdings Limited functions as an investment holding company, delivering sophisticated drug discovery and intelligent automation solutions across key markets including China, the United States, Europe, South Korea, and Japan. Its comprehensive drug discovery services encompass the entire research and development process, ranging from target validation and hit identification to lead generation, lead optimization, and PCC nomination. These services are adept across diverse therapeutic modalities, such as small molecules, antibodies, peptides, ADCs, and PROTACs. The company's intelligent automation solutions specifically utilize artificial intelligence and automation to facilitate the accelerated discovery and research of novel drugs and materials. Established in 2015 and based in Shenzhen, China, the firm was formerly known as QuantumPharm Inc. before officially changing its name to XtalPi Holdings Limited in December 2024.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.19% | +3.65% | -13.54% | -20.46% | -17.68% | -12.90% | +79.13% | +42.07% | +42.07% | +42.07% | +42.07% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%+193.5% ★
-
EPS growth Medical - Healthcare Information Services: +43.1%+103.8% ★
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%-58.1% Q4'25: +21.2%
-
EBIT margin Medical - Healthcare Information Services: +8.8%-63.5% Q4'25: -166.0%
-
ROIC Medical - Healthcare Information Services: +5.2%-17.6% Q4'25: -65.6%
-
Share dilution Medical - Healthcare Information Services: -0.1%+107.0%
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×-1.16× Q4'25: -0.27×
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 3 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
266.43M
est: 245.30M (+8.6%)
|
781.85M
est: 784.65M (-0.4%)
|
1.03B
952.58M – 1.11B
+31.5% YoY
|
1.42B
1.23B – 1.53B
+37.8% YoY
|
1.88B
1.67B – 2.03B
+32.5% YoY
|
| EBITDA |
-631.38M
est: -182.87M (-245.3%)
|
-383.89M
est: -584.96M (+34.4%)
|
-769.31M
-828.46M – -710.15M
-31.5% YoY
|
-1.06B
-1.14B – -914.03M
-37.8% YoY
|
-1.40B
-1.51B – -1.24B
-32.5% YoY
|
| EBIT |
-714.76M
est: -200.54M (-256.4%)
|
-496.50M
est: -641.47M (+22.6%)
|
-843.62M
-908.49M – -778.75M
-31.5% YoY
|
-1.16B
-1.25B – -1.00B
-37.8% YoY
|
-1.54B
-1.66B – -1.37B
-32.5% YoY
|
| Net Income |
-1.52B
est: -1.11B (-36.7%)
|
120.54M
est: -72.66M (+265.9%)
|
48.31M
41.18M – 53.02M
+166.5% YoY
|
225.02M
191.80M – 246.95M
+365.8% YoY
|
401.63M
342.35M – 440.78M
+78.5% YoY
|
| SGA |
551.32M
est: 328.83M (+67.7%)
|
478.35M
est: 1.05B (-54.5%)
|
1.38B
1.28B – 1.49B
+31.5% YoY
|
1.91B
1.64B – 2.05B
+37.8% YoY
|
2.53B
2.24B – 2.71B
+32.5% YoY
|
| EPS |
-0.79
est: -0.28 (-184.5%)
|
0.03
est: -0.02 (+275.4%)
|
0.01
0.01 – 0.01
+166.5% YoY
|
0.06
0.05 – 0.06
+365.8% YoY
|
0.10
0.09 – 0.11
+78.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X China Biotech ETF (HKD) 2820.HK | 1.56% | 1.25M | 0.68% |
| 2 | KraneShares MSCI All China Health Care Index ETF KURE | 0.95% | 758.9K | 0.79% |
| 3 | WisdomTree China ex-State-Owned Enterprises Fund CXSE | 0.12% | 580.7K | 0.32% |
| 4 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.08% | 11.19M | 0.06% |
| 5 | Xtrackers MSCI China UCITS ETF 1D XCS7.L | 0.07% | 1.40M | 0.28% |
| 6 | Xtrackers MSCI China UCITS ETF 1C XCS6.L | 0.07% | 1.40M | 0.65% |
| 7 | Global X MSCI China ETF (HKD) 3040.HK | 0.07% | 39.0K | 0.18% |
| 8 | iShares MSCI China UCITS ETF ICHN.AS | 0.07% | 1.75M | 0.28% |
| 9 | iShares MSCI China UCITS ETF ICHD.AS | 0.07% | 63.2K | 0.28% |
| 10 | iShares MSCI China ETF MCHI | 0.07% | 4.17M | 0.59% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Lipeng Lai | Co-Founder, Chief Innovation Officer & Executive Director | 5M | — |
| Jian Ma | Co-Founder, Chief Innovation Officer & Executive Director | 5M | — |
| Shuhao Wen | Co-Founder & Executive Chairman of Board | 5M | — |
| Yide Jiang | Chief Strategic Officer & Executive Director | 3M | — |
| Sau Ling Chan ACIS FCIS | Joint Company Secretary | — | female |
| Peiyu Zhang | Chief Scientific Officer | — | — |
| Feiran Zhou | Chief Financial Officer | — | male |
| Shimei Liu | Joint Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2228.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
